The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,985 | -39,596 |
| Non-cash interest expense | 2,100 | 4,200 |
| Change in accounts receivable | 0 | 0 |
| Change in inventory deposit | 0 | 0 |
| Change in inventory | 0 | - |
| Change in right of use asset | 0 | 0 |
| Change in accounts payable | 0 | 0 |
| Unearned sales revenue | 0 | - |
| Unearned service revenue | -25,000 | 62,500 |
| Change in lease liability | 0 | 0 |
| Net cash used in operating activities | -30,885 | 27,104 |
| Proceeds from long-term loan | 0 | - |
| Discount on long-term loan | 0 | 0 |
| Proceeds from issuance of common stock | 0 | 0 |
| Additional paid-capital | 0 | 0 |
| Stock subscription receivable | 0 | 0 |
| Net cash provided by financing activities | 0 | 0 |
| Net change in cash | -30,885 | 27,104 |
| Cash and cash equivalents at beginning of period | 49,404 | - |
| Cash and cash equivalents at end of period | 45,622 | - |
GOLDENWELL BIOTECH, INC. (GWLL)
GOLDENWELL BIOTECH, INC. (GWLL)